NCT04382664 2025-01-14
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
Phase 2 Completed
Clinical Trials
28 trialsNCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT00019890 2024-03-04
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01989572 2020-07-07
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT02451488 2020-02-10
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
Phase 4 Completed
NCT00003897 2019-11-19
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
University of Wisconsin, Madison
Phase 1 Completed
NCT00568763 2018-10-31
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00256282 2018-05-03
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
University of California, Irvine
Phase 2 Completed
NCT00471471 2017-06-22
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 1 Completed
NCT00948480 2016-07-15
DCVaccineMel
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00005610 2016-07-13
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00017121 2016-07-06
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00089063 2015-04-15
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089193 2014-12-23
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
University of Virginia
Phase 2 Completed
NCT00089206 2014-12-19
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Phase 2 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00003274 2014-05-22
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
University of Southern California
Phase 2 Completed
NCT00031733 2014-05-22
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Phase 2 Completed
NCT00436930 2014-01-10
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003362 2013-06-25
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00019331 2013-06-20
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019383 2013-06-20
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004184 2013-04-12
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00085423 2013-04-10
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00006243 2013-01-25
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase NA Completed
NCT00006385 2011-11-08
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed